Acute Myeloid Leukemia as a Trigger for Hemolytic-Uremic Syndrome

Acute myeloid leukemia (AML) has not been identified as a cause of secondary hemolytic-uremic syndrome (HUS). This case report describes a woman who developed severe HUS at the time of AML diagnosis and responded favorably to initial treatment with eculizumab, which stabilized her condition and allo...

ver descrição completa

Detalhes bibliográficos
Autores: El Bachouti, J, Domínguez-Guasch, A, Arce, Y, Oñate, G, Marco, H, Diaz, M, Guirado, L, Torra, R, Barros, X
Formato: artículo
Estado:Versión publicada
Fecha de publicación:2024
País:España
Recursos:Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)
Repositorio:r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
OAI Identifier:oai:iibsantpau.fundanetsuite.com:p18262
Acesso em linha:https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=18262
http://ddd.uab.cat/record/309299
Access Level:acceso abierto
Palavra-chave:acute myeloid leukemia
eculizumab
hemolytic uremic syndrome
id ES_9331c2fac380e8a2c482791dc47d5adf
oai_identifier_str oai:iibsantpau.fundanetsuite.com:p18262
network_acronym_str ES
network_name_str España
repository_id_str
spelling Acute Myeloid Leukemia as a Trigger for Hemolytic-Uremic SyndromeEl Bachouti, JDomínguez-Guasch, AArce, YOñate, GMarco, HDiaz, MGuirado, LTorra, RBarros, Xacute myeloid leukemiaeculizumabhemolytic uremic syndromeAcute myeloid leukemia (AML) has not been identified as a cause of secondary hemolytic-uremic syndrome (HUS). This case report describes a woman who developed severe HUS at the time of AML diagnosis and responded favorably to initial treatment with eculizumab, which stabilized her condition and allowed for treatment of the AML. After one year, with stable renal function and genetic studies reported as normal, eculizumab was successfully discontinued. The prompt use of eculizumab was critical to the patient's survival and improvement in renal function, highlighting the efficacy of early eculizumab treatment in secondary HUS.MDPI2024info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=18262http://ddd.uab.cat/record/309299Journal of Clinical MedicineISSN: 20770383reponame:r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pauinstname:Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)Inglésinfo:eu-repo/semantics/openAccessoai:iibsantpau.fundanetsuite.com:p182622026-06-14T12:41:47Z
dc.title.none.fl_str_mv Acute Myeloid Leukemia as a Trigger for Hemolytic-Uremic Syndrome
title Acute Myeloid Leukemia as a Trigger for Hemolytic-Uremic Syndrome
spellingShingle Acute Myeloid Leukemia as a Trigger for Hemolytic-Uremic Syndrome
El Bachouti, J
acute myeloid leukemia
eculizumab
hemolytic uremic syndrome
title_short Acute Myeloid Leukemia as a Trigger for Hemolytic-Uremic Syndrome
title_full Acute Myeloid Leukemia as a Trigger for Hemolytic-Uremic Syndrome
title_fullStr Acute Myeloid Leukemia as a Trigger for Hemolytic-Uremic Syndrome
title_full_unstemmed Acute Myeloid Leukemia as a Trigger for Hemolytic-Uremic Syndrome
title_sort Acute Myeloid Leukemia as a Trigger for Hemolytic-Uremic Syndrome
dc.creator.none.fl_str_mv El Bachouti, J
Domínguez-Guasch, A
Arce, Y
Oñate, G
Marco, H
Diaz, M
Guirado, L
Torra, R
Barros, X
author El Bachouti, J
author_facet El Bachouti, J
Domínguez-Guasch, A
Arce, Y
Oñate, G
Marco, H
Diaz, M
Guirado, L
Torra, R
Barros, X
author_role author
author2 Domínguez-Guasch, A
Arce, Y
Oñate, G
Marco, H
Diaz, M
Guirado, L
Torra, R
Barros, X
author2_role author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv acute myeloid leukemia
eculizumab
hemolytic uremic syndrome
topic acute myeloid leukemia
eculizumab
hemolytic uremic syndrome
description Acute myeloid leukemia (AML) has not been identified as a cause of secondary hemolytic-uremic syndrome (HUS). This case report describes a woman who developed severe HUS at the time of AML diagnosis and responded favorably to initial treatment with eculizumab, which stabilized her condition and allowed for treatment of the AML. After one year, with stable renal function and genetic studies reported as normal, eculizumab was successfully discontinued. The prompt use of eculizumab was critical to the patient's survival and improvement in renal function, highlighting the efficacy of early eculizumab treatment in secondary HUS.
publishDate 2024
dc.date.none.fl_str_mv 2024
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=18262
http://ddd.uab.cat/record/309299
url https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=18262
http://ddd.uab.cat/record/309299
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv MDPI
publisher.none.fl_str_mv MDPI
dc.source.none.fl_str_mv Journal of Clinical Medicine
ISSN: 20770383
reponame:r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname:Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)
instname_str Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)
reponame_str r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
collection r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869413546430824448
score 15,811543

Registos relacionados